Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak; Pramote Euasobhon; Suthanee Cenpakdee; Suratsawadee Wangnamthip; Pranee Rushatamukayanunt

doi:10.12659/MSM.945612

19 September 2024 : Clinical Research

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Sukunya Jirachaipitak^1ABCDEF, Pramote Euasobhon^1ABCDEFG*, Suthanee Cenpakdee^1ABEF, Suratsawadee Wangnamthip^1ABDE, Pranee Rushatamukayanunt^1ABDE

DOI: 10.12659/MSM.945612

Med Sci Monit 2024; 30:e945612

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Adverse events of oxcarbazepine treatment. Data are presented as numbers (%).

Adverse effects	N=32
Daytime somnolence	19 (59.4)
Tolerable dizziness	15 (46.9)
Nausea	11 (34.4)
Hyponatremia	5 (15.6)
Vomiting	4 (12.5)

Back to the Article

Intravenous Lidocaine Response as a Predictor for Oral Oxcarbazepine Efficacy in Neuropathic Pain Syndrome: A Prospective Cohort Study

Your Privacy